🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients

RecruitingNAAges 18 Years - anyAllRoyal Marsden NHS Foundation Trust
NCT07673861 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

ctDNA stands for circulating tumour DNA. As ctDNA is released by tumour cells into the blood stream, taking a blood sample and analysing it for ctDNA, can provide a lot of useful information about a patient's cancer. In certain situations, ctDNA can be used to screen for or detect cancer early, to aid clinical decisions about which treatment to give a patient, to provide information about if a cancer has become resistant to treatment, or provide information about how much cancer may be left after treatment (residual disease). The aim of this trial is to establish the clinical utility of implementing ctDNA testing in cancer patients with a view to enhance the delivery of personalised care within the National Health Service in the United Kingdom (UK). One hundred patients will be recruited, with 20 from each of the following cancer types: * Non-small cell lung cancer * Gastrointestinal

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria All cohorts: * Age ≥18 years old * Ability to provide written informed consent * Presence of metastatic or unresectable disease * Being reviewed and treated through medical oncology service at Royal Marsden Hospital Cohort 1: Locally Advanced/Metastatic NSCLC * Oncogene-addicted NSCLC (i.e. ESCAT Tier 1 oncogenic drivers: EGFR/ALK/ROS1/RET/MET/BRAF/NTRK/HER2/KRAS), AND * Progressive disease on targeted therapy (any line) within the 6 weeks prior to consent Cohort 2: Locally Advanced/Metastatic GIST * Locally advanced/metastatic gastrointestinal stromal tumour (GIST), AND * Progressive disease on targeted therapy (any line) within the 6 weeks prior to consent Cohort 3: Metastatic Colorectal Cancer • Metastatic colorectal cancer, left sided, RAS wild type, HER2 any status, AND * If HER2 negative or unknown: progressive disease on systemic anti-cancer therapy (SACT) with an anti-EGFR agent (e.g. cetuximab) within the 6 weeks prior to consent * If HER2 positive: progressive disease on first line systemic anti-cancer therapy (SACT) +/- an anti-EGFR agent within the 6 weeks prior to consent Cohort 4: Locally Advanced/Metastatic BTC * Identified targetable mutation (IDH1 mutation/HER2 amplification/FGFR2 fusion or rearrangement/NTRK fusion/BRAF V600E mutation/MMR deficiency \[dMMR\]), AND * Progressive disease on targeted therapy (any line) demonstrated within the 6 weeks prior to consent Cohort 5: Advanced/Metastatic ovarian cancer * Diagnosis of advanced/metastatic high-grade ovarian cancer, AND * Known BRCA status, AND * Progressive disease on a PARP-inhibitor (with or without bevacizumab) following platinum-based therapy in the 1st line maintenance setting, within the 6 weeks prior to consent Exclusion Criteria All cohorts: * Medically unstable to commit to sampling required for the study * ECOG performance status ≥3
💊

What it tests

  • Marsden360 ctDNA test and GTAB review
📍

Where

1 site
Royal Marsden NHS Foundation Trust
London, United Kingdom
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy